Zofia Szular
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zofia Szular has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Adam Krzaczkowski
Infant Jesus Clinical Hospital, Medical University of Warsaw, Poland
3 shared publications - Emilia Niedzieska
Central Clinical Hospital, Medical University of Warsaw, Poland
3 shared publications - Joanna Szuba
Infant Jesus Clinical Hospital, Medical University of Warsaw, Poland
3 shared publications - Justyna Drożdżał
Infant Jesus Clinical Hospital, Medical University of Warsaw, Poland
3 shared publications - Katarzyna Ziemek
Infant Jesus Clinical Hospital, Medical University of Warsaw, Poland
3 shared publications - Magdalena Rędaszka
Clinical Hospital of Infant Jesus in Warsaw
3 shared publications
Latest Publications
- Open Access
- 9 August 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 44, 62865
Bridge-Enhanced ACL Repair: Novel approach and emerging opportunities in anterior cruciate ligament injury management - literature review
Anterior cruciate ligament injury is one of the most common trauma in sport. It leads to long-term exclusion from physical activity, poor quality of life and may result in posttraumatic osteoarthritis. The current gold standard in managing ACL rupture is reconstruction procedure but it is associated with complications such as chronic pain of the knee and muscle weakness. Furthermore, a significant number of patients do not regain their pre-injury level of activity. This study examines research on the BEAR method, being the novel approach in ACL injury management. In this technique, a bovine-derived implant is inserted within the patient's native ligament, allowing it to heal properly without being replaced by a graft. This is achieved by preserving blood clot formation within the joint, which was a limitation of primary open repair cases. It was found that patients who have undergone the BEAR procedure presented better hamstring strength compared to the ACL reconstruction group, have earlier resolution of symptoms, faster psychological preparedness for returning to sport, low complication rate and no donor-site morbidity. It was stated that BEAR itself is non-inferior to ACLR in terms of Patient-Reported Outcome Measures. The efficacy of this technique in reducing posttraumatic osteoarthritis remains to be established. However, findings from animal studies indicate promising outcomes. Larger-scale studies are needed to fully evaluate this modern approach.
- 9 August 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 44, 62865
Open AccessBridge-Enhanced ACL Repair: Novel approach and emerging opportunities in anterior cruciate ligament injury management - literature review
Anterior cruciate ligament injury is one of the most common trauma in sport. It leads to long-term exclusion from physical activity, poor quality of life and may result in posttraumatic osteoarthritis. The current gold standard in managing ACL rupture is reconstruction procedure but it is associated with complications such as chronic pain of the knee and muscle weakness. Furthermore, a significant number of patients do not regain their pre-injury level of activity. This study examines research on the BEAR method, being the novel approach in ACL injury management. In this technique, a bovine-derived implant is inserted within the patient's native ligament, allowing it to heal properly without being replaced by a graft. This is achieved by preserving blood clot formation within the joint, which was a limitation of primary open repair cases. It was found that patients who have undergone the BEAR procedure presented better hamstring strength compared to the ACL reconstruction group, have earlier resolution of symptoms, faster psychological preparedness for returning to sport, low complication rate and no donor-site morbidity. It was stated that BEAR itself is non-inferior to ACLR in terms of Patient-Reported Outcome Measures. The efficacy of this technique in reducing posttraumatic osteoarthritis remains to be established. However, findings from animal studies indicate promising outcomes. Larger-scale studies are needed to fully evaluate this modern approach.
- Open Access
- 10 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 43, 62381
The Impact of physical activity and related factors on the risk of melanoma development and progression of the disease - A literature review
Introduction In 2020, around 325,000 new melanoma cases were diagnosed globally, with 57,000 resulting deaths. The highest incidence was observed in Australia and New Zealand, while much lower rates occurred in African and Asian countries. Melanoma was generally more common in males. The global rise in melanoma—possibly linked to increased travel and tanning device use—calls for identification of modifiable risk factors and predictors. Lifestyle elements, especially physical activity and body weight, play a major role in cancer risk and progression. Purpose of research This review aims to explore how physical activity and related factors affect melanoma risk and disease progression. It also examines sun-protection awareness, behaviors, and melanoma risk among outdoor athletes. Materials and methods In 2025, a literature review was conducted using PubMed, Web of Science, and Google Scholar, focusing on English-language studies analyzing the link between amateur or professional physical activity and melanoma. Search terms included "physical activity," "exercise," "athletes," "melanoma," and "photoprotection." Summary Numerous preclinical studies examine the influence of physical activity on the tumor microenvironment. Another key focus is the impact of exercise on melanoma patients undergoing immunotherapy. Epidemiological data emphasize sun exposure as a major risk factor, particularly for physically active individuals. Therefore, consistent use of sun protection is essential from an early age, especially for both professional and recreational athletes. Primary care physicians should conduct regular skin exams for active individuals, particularly swimmers. Future research should explore both behavioral and biological mechanisms and determine whether physical activity independently affects melanoma risk markers, such as telomere length and naevus count.
- 10 July 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 43, 62381
Open AccessThe Impact of physical activity and related factors on the risk of melanoma development and progression of the disease - A literature review
Introduction In 2020, around 325,000 new melanoma cases were diagnosed globally, with 57,000 resulting deaths. The highest incidence was observed in Australia and New Zealand, while much lower rates occurred in African and Asian countries. Melanoma was generally more common in males. The global rise in melanoma—possibly linked to increased travel and tanning device use—calls for identification of modifiable risk factors and predictors. Lifestyle elements, especially physical activity and body weight, play a major role in cancer risk and progression. Purpose of research This review aims to explore how physical activity and related factors affect melanoma risk and disease progression. It also examines sun-protection awareness, behaviors, and melanoma risk among outdoor athletes. Materials and methods In 2025, a literature review was conducted using PubMed, Web of Science, and Google Scholar, focusing on English-language studies analyzing the link between amateur or professional physical activity and melanoma. Search terms included "physical activity," "exercise," "athletes," "melanoma," and "photoprotection." Summary Numerous preclinical studies examine the influence of physical activity on the tumor microenvironment. Another key focus is the impact of exercise on melanoma patients undergoing immunotherapy. Epidemiological data emphasize sun exposure as a major risk factor, particularly for physically active individuals. Therefore, consistent use of sun protection is essential from an early age, especially for both professional and recreational athletes. Primary care physicians should conduct regular skin exams for active individuals, particularly swimmers. Future research should explore both behavioral and biological mechanisms and determine whether physical activity independently affects melanoma risk markers, such as telomere length and naevus count.
- Open Access
- 17 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 42, 60806
Hipercium species in the treatment of depression - a literature overview
Hypericum perforatum, commonly known as St. John’s wort, has gained considerable attention as a herbal alternative in the treatment of mild to moderate depression. Given its favorable safety profile, natural origin, and evidence-based efficacy, it may represent a valuable support tool in mental health care, including among physically active individuals. The plant’s therapeutic potential stems from the synergistic action of compounds such as hyperforin and hypericin, which modulate neurotransmitter systems and neuroinflammation. Clinical studies and meta-analyses confirm that H. perforatum demonstrates comparable effectiveness to conventional antidepressants, while showing fewer side effects. Although its interaction with other medications requires caution, the growing interest in phytotherapy highlights its relevance in supporting psychological well-being, especially in stress-prone populations, such as athletes or individuals seeking non-pharmacological interventions.
- 17 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 42, 60806
Open AccessHipercium species in the treatment of depression - a literature overview
Hypericum perforatum, commonly known as St. John’s wort, has gained considerable attention as a herbal alternative in the treatment of mild to moderate depression. Given its favorable safety profile, natural origin, and evidence-based efficacy, it may represent a valuable support tool in mental health care, including among physically active individuals. The plant’s therapeutic potential stems from the synergistic action of compounds such as hyperforin and hypericin, which modulate neurotransmitter systems and neuroinflammation. Clinical studies and meta-analyses confirm that H. perforatum demonstrates comparable effectiveness to conventional antidepressants, while showing fewer side effects. Although its interaction with other medications requires caution, the growing interest in phytotherapy highlights its relevance in supporting psychological well-being, especially in stress-prone populations, such as athletes or individuals seeking non-pharmacological interventions.
- Open Access
- 25 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12631
Efficacy and Safety of Agomelatine in Depressed Patients with Diabetes: A Systematic Review and Meta-Analysis
Major depressive disorder (MDD) and diabetes mellitus (DM) remain among the most prevalent diseases and the most significant challenges faced by medicine in the 21st century. The frequent co-occurrence and bidirectional relationship between the two conditions necessitates the identification of treatment strategies that benefit both. The purpose of this study was to systematically review and meta-analyze data on the efficacy and safety of agomelatine (AGO) in the treatment of patients with depression with comorbid diabetes to explore its potential mechanism of action in both diseases and its impact on diabetic parameters. Following PRISMA guidelines, a total of 11 studies were identified, both preclinical and clinical trials. Agomelatine has shown great potential as a treatment option for patients with diabetes and comorbid depression and anxiety. In addition to improving depressive and anxiety symptoms, it is also beneficial in glycemic control. A meta-analysis demonstrated a statistically significant reduction in glycated hemoglobin (HbA1C) and fasting blood glucose (FBG) levels following AGO administration over a period of 8–16 weeks. The administration of agomelatine was found to result in a significantly greater reduction in HbA1C than that observed with the selective serotonin reuptake inhibitor (SSRI) medications (namely fluoxetine, sertraline, and paroxetine) during 12–16 weeks of therapy. Furthermore, AGO has been found to be at least as effective as SSRIs in reducing depressive symptoms and more effective than SSRIs in reducing anxiety symptoms. The safety of such treatment is similar to SSRIs; no severe adverse events were reported, and the incidence of some side effects, such as insomnia and sexual dysfunction, are even less often reported. Particularly promising is also its potential action in improving some diabetic complications reported in preclinical trials. This might be through mechanisms involving the reduction in oxidative stress, anti-inflammatory effects, and potentially noradrenergic or NMDA receptor modulation. Further clinical studies on larger sample sizes, as well as elucidating its mechanisms of action, especially in the context of diabetic complications, are needed. Research should also focus on identifying the patient subpopulations most likely to benefit from agomelatine treatment.
- 25 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (23) , 12631
Open AccessEfficacy and Safety of Agomelatine in Depressed Patients with Diabetes: A Systematic Review and Meta-Analysis
Major depressive disorder (MDD) and diabetes mellitus (DM) remain among the most prevalent diseases and the most significant challenges faced by medicine in the 21st century. The frequent co-occurrence and bidirectional relationship between the two conditions necessitates the identification of treatment strategies that benefit both. The purpose of this study was to systematically review and meta-analyze data on the efficacy and safety of agomelatine (AGO) in the treatment of patients with depression with comorbid diabetes to explore its potential mechanism of action in both diseases and its impact on diabetic parameters. Following PRISMA guidelines, a total of 11 studies were identified, both preclinical and clinical trials. Agomelatine has shown great potential as a treatment option for patients with diabetes and comorbid depression and anxiety. In addition to improving depressive and anxiety symptoms, it is also beneficial in glycemic control. A meta-analysis demonstrated a statistically significant reduction in glycated hemoglobin (HbA1C) and fasting blood glucose (FBG) levels following AGO administration over a period of 8–16 weeks. The administration of agomelatine was found to result in a significantly greater reduction in HbA1C than that observed with the selective serotonin reuptake inhibitor (SSRI) medications (namely fluoxetine, sertraline, and paroxetine) during 12–16 weeks of therapy. Furthermore, AGO has been found to be at least as effective as SSRIs in reducing depressive symptoms and more effective than SSRIs in reducing anxiety symptoms. The safety of such treatment is similar to SSRIs; no severe adverse events were reported, and the incidence of some side effects, such as insomnia and sexual dysfunction, are even less often reported. Particularly promising is also its potential action in improving some diabetic complications reported in preclinical trials. This might be through mechanisms involving the reduction in oxidative stress, anti-inflammatory effects, and potentially noradrenergic or NMDA receptor modulation. Further clinical studies on larger sample sizes, as well as elucidating its mechanisms of action, especially in the context of diabetic complications, are needed. Research should also focus on identifying the patient subpopulations most likely to benefit from agomelatine treatment.
- Open Access
- 16 May 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (10) , 3497
Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
The effects of celecoxib on a broad spectrum of mood disorders and on inflammatory parameters have not yet been comprehensively evaluated. The aim of this study was to systematically summarize the available knowledge on this topic. Data from both preclinical and clinical studies were analyzed, considering the efficacy and safety of celecoxib in the treatment of mood disorders, as well as the correlation of inflammatory parameters with the effect of celecoxib treatment. Forty-four studies were included. We found evidence supporting the antidepressant efficacy of celecoxib in a dose of 400 mg/day used for 6 weeks as an add-on treatment in major depression (SMD = −1.12 [95%Cl: −1.71,−0.52], p = 0.0002) and mania (SMD = −0.82 [95% CI:−1.62,−0.01], p = 0.05). The antidepressant efficacy of celecoxib in the above dosage used as sole treatment was also confirmed in depressed patients with somatic comorbidity (SMD = −1.35 [95% CI:−1.95,−0.75], p < 0.0001). We found no conclusive evidence for the effectiveness of celecoxib in bipolar depression. Celecoxib at a dose of 400 mg/d used for up to 12 weeks appeared to be a safe treatment in patients with mood disorders. Although an association between celecoxib response and inflammatory parameters has been found in preclinical studies, this has not been confirmed in clinical trials. Further studies are needed to evaluate the efficacy of celecoxib in bipolar depression, as well as long-term studies evaluating the safety and efficacy of celecoxib in recurrent mood disorders, studies involving treatment-resistant populations, and assessing the association of celecoxib treatment with inflammatory markers.
- 16 May 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (10) , 3497
Open AccessCelecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
The effects of celecoxib on a broad spectrum of mood disorders and on inflammatory parameters have not yet been comprehensively evaluated. The aim of this study was to systematically summarize the available knowledge on this topic. Data from both preclinical and clinical studies were analyzed, considering the efficacy and safety of celecoxib in the treatment of mood disorders, as well as the correlation of inflammatory parameters with the effect of celecoxib treatment. Forty-four studies were included. We found evidence supporting the antidepressant efficacy of celecoxib in a dose of 400 mg/day used for 6 weeks as an add-on treatment in major depression (SMD = −1.12 [95%Cl: −1.71,−0.52], p = 0.0002) and mania (SMD = −0.82 [95% CI:−1.62,−0.01], p = 0.05). The antidepressant efficacy of celecoxib in the above dosage used as sole treatment was also confirmed in depressed patients with somatic comorbidity (SMD = −1.35 [95% CI:−1.95,−0.75], p < 0.0001). We found no conclusive evidence for the effectiveness of celecoxib in bipolar depression. Celecoxib at a dose of 400 mg/d used for up to 12 weeks appeared to be a safe treatment in patients with mood disorders. Although an association between celecoxib response and inflammatory parameters has been found in preclinical studies, this has not been confirmed in clinical trials. Further studies are needed to evaluate the efficacy of celecoxib in bipolar depression, as well as long-term studies evaluating the safety and efficacy of celecoxib in recurrent mood disorders, studies involving treatment-resistant populations, and assessing the association of celecoxib treatment with inflammatory markers.